7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 
      
    		                                                 
      operating activities
    		                                                 
      net income
    		-103,433,000 -112,020,000 -89,289,000 -96,523,000 947,915,000 -96,118,000 -81,549,000 -95,940,000 -91,324,000 -83,806,000 -81,018,000 36,526,000 -81,747,000 -91,806,000 -94,774,000 -94,627,000 -88,766,000 -86,217,000 1,874,325,000 -97,657,000 -98,979,000 -90,478,000 -40,256,000 -102,350,000 -106,173,000 -109,871,000 -93,078,000 -91,794,000 -94,664,000 -68,745,000 -90,825,000 -88,285,000 -77,137,000 -83,082,000 -66,166,000 -56,486,000 -62,834,000 -55,953,000 -23,198,000 -40,622,000 -40,256,000 -31,897,000 -4,957,000 -26,664,000 3,704,000 -18,296,000 -12,248,000 -12,382,000 -11,177,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                 
      depreciation and amortization
    		1,374,000 1,259,000 1,278,000 1,367,000 1,345,000 1,593,000 1,348,000 1,403,000 1,623,000 1,807,000 1,790,000 1,814,000 1,981,000 2,291,000 2,478,000 2,202,000 2,209,000 2,350,000 2,479,000 2,677,000                              
      stock-based compensation expense
    		12,377,000 14,692,000 11,359,000 10,903,000 11,145,000 11,565,000 9,234,000 13,814,000 9,076,000 11,737,000 10,139,000 11,465,000 11,156,000 11,165,000 15,510,000 11,621,000 12,148,000 14,885,000 14,854,000 16,595,000 18,407,000 20,430,000 19,690,000 17,130,000 18,588,000 18,547,000 18,108,000 18,187,000 24,193,000 16,455,000 14,522,000 12,681,000 12,207,000 12,187,000 10,734,000 9,840,000 12,143,000 10,996,000 9,107,000 9,353,000 9,373,000 8,177,000 5,060,000 4,728,000 2,892,000 2,381,000 1,505,000 1,165,000 1,112,000 
      net accretion of discount on marketable securities
    		-1,674,000 -2,420,000 -1,348,000 -5,616,000 -3,734,000 -2,609,000 -2,527,000                                           
      gain on disposal of property and equipment
    		299,000     0 -39,000    -150,000                                       
      non-cash operating lease expense
    		3,135,000 3,076,000 3,018,000 2,962,000 2,909,000 2,856,000 2,803,000 2,753,000 2,704,000 2,655,000 2,608,000 2,563,000 2,513,000 2,483,000 2,436,000 2,408,000 2,369,000 2,343,000 2,417,000 2,291,000 2,256,000 2,232,000 2,203,000 2,191,000 2,133,000 2,123,000 2,085,000                       
      expense associated with license agreement
    		0       0                                          
      realized gain on investments
    		 0 -2,000 1,000 -15,000 -1,000 -152,000 0                                          
      gain on sale of contingent payments
    		   0                                              
      milestone payment from gain on sale of oncology business
    		   0                                              
      changes in operating assets and liabilities:
    		                                                 
      accounts receivable
    		-43,000 -1,642,000 765,000 -991,000 644,000 -309,000 -643,000 -1,634,000 1,075,000 -473,000 428,000 -388,000 -220,000 -1,058,000 -540,000     -2,339,000 -6,966,000 -210,000 -2,861,000 -1,846,000 41,000 -2,792,000 721,000 -2,445,000                      
      inventory
    		-1,186,000 -1,243,000 -1,989,000 -1,187,000 -2,492,000 -867,000 -3,994,000 -1,802,000 -1,603,000 -4,297,000 -2,882,000 -3,316,000 -1,116,000 -1,575,000 -2,485,000     -3,327,000 -140,000 -1,453,000 -2,447,000 -1,482,000 -1,190,000 -2,331,000 -1,459,000 -6,000                      
      prepaid expenses and other current and non-current assets
    		1,519,000 -1,622,000 -2,124,000 -948,000 -5,349,000 4,577,000 -4,091,000 3,393,000 -1,663,000 2,451,000 -348,000 7,479,000 -4,099,000 -165,000 -3,391,000 -7,597,000 -10,795,000 -4,833,000 -3,621,000 5,434,000 -1,676,000 2,417,000 -6,774,000 -4,190,000 -1,035,000 -344,000 -2,173,000 -563,000 -702,000 512,000 1,901,000 -2,086,000 -2,027,000 1,008,000 -3,425,000 -231,000              
      accounts payable
    		1,807,000 3,905,000 -2,821,000 -756,000 7,089,000 -1,162,000 1,430,000 -3,532,000 1,636,000 2,959,000 -9,796,000 8,064,000 2,615,000 -2,236,000 -5,007,000 5,200,000 2,224,000 -2,620,000 -2,941,000 13,529,000 -116,000 -5,515,000 -2,009,000 1,067,000 4,523,000 3,065,000 -4,939,000 342,000 368,000 -1,729,000 -4,469,000 4,587,000 -4,188,000 5,924,000 -994,000 1,833,000 -2,087,000 4,048,000 -293,000 5,539,000 -114,000 1,455,000 -2,665,000 5,223,000 670,000 964,000 720,000 1,208,000 -907,000 
      accrued expenses and other current liabilities
    		1,928,000 14,528,000 -26,100,000  -3,435,000 11,613,000 -18,038,000  1,301,000 6,730,000 -7,891,000  1,373,000 8,636,000 -12,220,000  -120,000 10,150,000 -12,697,000                               
      income taxes payable
    		0 -683,000 -188,000 -51,811,000                                            -3,684,000 116,000 
      operating lease liabilities
    		-4,245,000 -4,180,000 -4,048,000 -3,846,000 -3,786,000 -3,727,000 -3,649,000 -3,502,000 -3,448,000 -3,392,000 -3,321,000 -3,182,000 -2,095,000 -3,146,000 -2,405,000 -2,212,000 -1,684,000 -2,127,000 -1,504,000 -2,015,000 -1,963,000 -1,920,000 -2,229,000 -2,671,000 -541,000 -1,520,000 -2,129,000                       
      other non-current liabilities
    		-11,000        0 -157,000 -1,966,000  0                                     
      net cash from operating activities
    		-88,151,000 -77,124,000 -111,489,000 -133,167,000 -84,218,000 -72,589,000 -99,867,000 -72,488,000 -61,643,000 -66,748,000 -95,183,000 -66,163,000 -71,351,000 -74,229,000 -97,735,000 9,141,000 -85,184,000 -117,294,000 -120,749,000 -49,397,000 -68,207,000 -67,797,000 -105,358,000 -93,611,000 -85,589,000 -88,151,000 -103,271,000 -74,187,000 -63,839,000 -67,395,000 -99,000,000 -74,454,000 -77,715,000 -58,989,000 -74,074,000 -51,223,000 -49,030,000 157,824,000 -19,009,000 -30,529,000 -24,815,000 3,980,000 -25,585,000 -7,775,000 -23,467,000 -1,071,000 -27,040,000 -13,617,000 -14,980,000 
      capex
    		-1,341,000 -875,000 -545,000 -967,000 -419,000 -158,000 -141,000 -193,000 -361,000 3,000 -399,000 -113,000 -38,000 -1,926,000 -2,804,000 -3,310,000 452,000 -199,000 -1,006,000 -737,000 -8,640,000 -6,056,000 989,000 -3,745,000 -484,000 -1,463,000 -1,311,000 -448,000 -4,004,000 -601,000 -827,000 -495,000 -3,176,000 135,000 -80,000 -1,222,000 -4,289,000 -1,981,000 -1,926,000 -2,186,000 -3,750,000 -10,882,000 2,805,000 -1,489,000 -443,000 -87,000 0 -219,000 -99,000 
      free cash flows
    		-89,492,000 -77,999,000 -112,034,000 -134,134,000 -84,637,000 -72,747,000 -100,008,000 -72,681,000 -62,004,000 -66,745,000 -95,582,000 -66,276,000 -71,389,000 -76,155,000 -100,539,000 5,831,000 -84,732,000 -117,493,000 -121,755,000 -50,134,000 -76,847,000 -73,853,000 -104,369,000 -97,356,000 -86,073,000 -89,614,000 -104,582,000 -74,635,000 -67,843,000 -67,996,000 -99,827,000 -74,949,000 -80,891,000 -58,854,000 -74,154,000 -52,445,000 -53,319,000 155,843,000 -20,935,000 -32,715,000 -28,565,000 -6,902,000 -22,780,000 -9,264,000 -23,910,000 -1,158,000 -27,040,000 -13,836,000 -15,079,000 
      investing activities
    		                                                 
      purchases of marketable securities
    		-174,981,000 -130,797,000 -174,903,000 -198,326,000 -995,503,000 -104,545,000 -244,059,000 -90,440,000 -95,004,000 -104,135,000 -128,351,000 -248,563,000 -174,471,000 -251,831,000 -355,916,000 -426,810,000 -452,515,000 -437,033,000 -61,863,000 -126,406,000 -241,023,000 -134,690,000 -54,911,000 -293,744,000 -50,591,000 -66,810,000 -77,421,000 -177,952,000 -162,704,000 -261,693,000 -330,971,000 -84,177,000 -135,969,000 -441,816,000 -26,740,000 -138,480,000 -141,298,000 -15,126,000 -211,163,000 -134,520,000 -112,452,000 -70,679,000 -35,526,000 -621,836,000 -89,045,000 -91,526,000 -34,812,000 -26,551,000 -96,303,000 
      proceeds from maturities and sales of marketable securities
    		272,091,000 220,638,000 288,256,000 150,135,000 157,579,000 141,947,000 368,722,000 186,187,000 151,039,000 151,257,000 186,196,000 198,879,000 278,579,000 336,570,000 332,147,000 336,893,000 219,762,000 139,133,000 134,016,000 198,819,000 119,983,000 161,382,000 167,501,000 115,795,000 133,010,000 132,561,000 210,811,000 166,200,000 168,615,000 166,795,000 164,871,000 127,305,000 204,405,000 167,126,000 136,585,000 62,184,000 81,980,000 53,600,000 198,868,000 157,664,000 145,908,000 113,767,000 84,311,000 336,023,000 74,004,000 72,941,000 22,560,000 6,360,000 15,680,000 
      payments associated with license agreement
    		0       0                                          
      proceeds from sale of contingent payments
    		   0                                              
      proceeds from milestone payment from gain on sale of oncology business
    		   0                                              
      purchases of property and equipment
    		-1,555,000 -875,000 -766,000 -967,000 -419,000 -158,000 -141,000 -234,000 -369,000 3,000 -399,000 -113,000 -38,000 -1,926,000 -2,804,000 -4,502,000 22,000 -249,000 -1,012,000 -1,017,000 -5,204,000 -4,233,000 -4,455,000 -6,824,000 -2,038,000 -1,271,000 -2,038,000 -1,053,000 -3,140,000 -1,361,000 -1,432,000 -1,280,000 -2,019,000 -1,035,000 -293,000 -1,222,000 -3,426,000 -2,734,000 -2,533,000 -2,186,000 -3,299,000 -10,882,000 -3,797,000 -1,489,000 -628,000 -86,000 -13,000 -219,000 -99,000 
      proceeds from sale of equipment
    		   0 0 0 40,000 0 1,175,000 0 150,000                                       
      net cash from investing activities
    		95,555,000 78,966,000 112,587,000 -49,158,000 250,793,000 37,244,000 124,562,000 95,513,000 39,341,000 47,125,000 57,596,000 82,951,000 104,070,000 82,813,000 -26,573,000 -1,897,355,000 -232,731,000 -298,149,000 1,874,077,000 71,396,000 -126,244,000 22,459,000 108,135,000 -184,773,000 80,381,000 64,480,000 131,352,000 -12,805,000 2,771,000 -96,259,000 -167,532,000 41,848,000 66,417,000 -275,725,000 109,552,000 -77,518,000 -62,744,000 35,740,000 -14,828,000 20,958,000 30,157,000 32,206,000 44,988,000 -287,302,000 -15,098,000 -18,671,000 -12,265,000 -20,410,000 -80,722,000 
      financing activities
    		                                                 
      net proceeds from stock option exercises and employee stock purchase plan
    		4,435,000 65,000 1,619,000 4,842,000 2,637,000 1,099,000 5,864,000 847,000 1,882,000 237,000 2,467,000 105,000 1,271,000 16,000 1,289,000 267,000 4,009,000 25,673,000 7,347,000 668,000 3,532,000 1,652,000 5,465,000 518,000 3,337,000 3,808,000 4,860,000 1,016,000 7,223,000 9,711,000 12,259,000  5,515,000 2,699,000 4,146,000  1,202,000 1,449,000 1,108,000  2,173,000 1,091,000 2,029,000       
      net cash from financing activities
    		4,435,000 65,000 1,619,000 4,842,000 2,637,000 1,099,000 5,864,000 847,000 1,882,000 237,000 2,467,000 22,000 1,187,000 -67,000 1,208,000 -18,586,000 -250,985,000 -503,458,000 7,261,000 582,000 3,448,000 252,103,000 5,385,000 277,606,000 3,337,000 3,808,000 4,860,000 1,016,000 7,223,000 9,508,000 528,277,000 2,589,000 5,322,000 273,153,000 4,046,000 3,993,000 163,228,000 1,449,000 1,108,000 1,287,000 2,173,000 1,091,000 1,822,000 239,059,000 367,000 95,152,000 582,000 -424,000 124,232,000 
      net change in cash and cash equivalents
    		11,839,000 1,907,000 2,717,000 -177,483,000 169,212,000 -34,246,000 30,559,000 23,872,000 -20,420,000 -19,386,000 -35,120,000 16,810,000 33,906,000 8,517,000 -123,100,000 -197,098,000 -568,900,000 -918,901,000 1,760,589,000 22,581,000 -191,003,000 206,765,000 8,162,000 -778,000 -1,871,000 -19,863,000 32,941,000 -85,976,000 -53,845,000 -154,146,000 261,745,000 -30,017,000 -5,976,000 -61,561,000 39,524,000               
      cash and cash equivalents at beginning of the period
    		0 0 76,247,000 0 0 0 88,205,000 0 0 0 139,259,000 0 0 0 203,126,000 0 0 0 127,436,000 0 0 0 80,931,000 0 0 0 70,502,000 0 0 0 102,724,000 0 0 0 160,754,000 0 0 0 71,764,000 0 0 0 14,031,000 0 0 0 71,560,000 0 0 
      cash and cash equivalents at end of the period
    		11,839,000 1,907,000 78,964,000 -177,483,000 169,212,000 -34,246,000 118,764,000 23,872,000 -20,420,000 -19,386,000 104,139,000 16,810,000 33,906,000 8,517,000 80,026,000 -197,098,000 -568,900,000 -918,901,000 1,888,025,000 22,581,000 -191,003,000 206,765,000 89,093,000 -778,000 -1,871,000 -19,863,000 103,443,000 -85,976,000 -53,845,000 -154,146,000 364,469,000 -30,017,000 -5,976,000 -61,561,000 200,278,000 -124,748,000 51,454,000 195,013,000 39,035,000 -8,284,000 7,515,000 37,277,000 35,256,000 -56,018,000 -38,198,000 75,410,000 32,837,000 -34,451,000 28,530,000 
      supplemental disclosure of non-cash investing and financing transactions
    		                                                 
      additions to property and equipment in accounts payable
    		214,000                                                 
      net cash taxes paid
    		65,000       -17,000                                          
      adjustments to reconcile net income from operations to net cash from operating activities:
    		                                                 
      additions to property and equipment in accounts payable and accrued expenses
    		  221,000     41,000 8,000       1,192,000 430,000 50,000 6,000 280,000 -3,436,000 -1,823,000 5,444,000 3,079,000 1,554,000 -192,000 727,000 605,000 -864,000 760,000 605,000 785,000 -1,157,000 1,170,000 213,000      -451,000         
      net cash taxes (returned) paid
    		  188,000   -78,000 -525,000                                           
      other receivables
    		           -157,000 -1,070,000 2,661,000 -987,000 2,612,000 1,141,000                       -381,000 2,289,000 1,625,000 -4,573,000       
      accrued expenses
    		                   10,598,000 8,757,000 6,372,000 -14,967,000 2,631,000 -2,469,000 12,168,000 -5,097,000 17,160,000 -696,000 9,303,000 -17,144,000 2,764,000 1,150,000                 
      other liabilities
    		                                                 
      payments on financing lease obligations
    		           -83,000 -84,000 -83,000 -81,000 195,000 -603,000 -84,000 -86,000 -86,000 -84,000 -86,000 -80,000                           
      supplemental disclosure of non-cash investing and financing transactions:
    		                                                 
      (gain) loss on disposal of property and equipment
    		                                                 
      less: net income from discontinued operations
    		               3,957,000 -4,507,000 -3,427,000 1,965,202,000                               
      net income from continuing operations
    		           36,526,000 -81,747,000 -91,806,000 -94,774,000 -98,584,000 -84,259,000 -82,790,000 -90,877,000                               
      net (accretion of discount) amortization of premium on marketable securities
    		       -393,000 1,080,000                                         
      net cash from operating activities - continuing operations
    		            -71,351,000 -74,229,000 -97,735,000  -74,866,000 -69,003,000 -90,226,000                               
      net cash from operating activities - discontinued operations
    		               -4,102,000 -10,318,000 -48,291,000 -30,523,000                               
      net cash from investing activities - continuing operations
    		            104,070,000 82,813,000 -26,573,000  -232,731,000 -298,149,000 71,141,000                               
      net cash from investing activities - discontinued operations
    		               0 0 0 1,802,936,000                               
      purchase of treasury stock
    		               -19,048,000 -254,391,000                                 
      financing lease liabilities arising from obtaining financing lease assets
    		               0 0                                 
      loss on disposal of property and equipment
    		            19,000   3,000 -3,000               0 0                 
      cash taxes paid
    		                                                 
      net amortization of premium (accretion of discount) on marketable securities
    		          -2,776,000  -661,000 232,000 1,150,000 1,623,000 1,904,000 1,758,000 1,664,000                               
      deferred revenue
    		              2,500,000                                 -6,268,000 -6,268,000 
      net cash from financing activities - discontinued operations
    		                                                 
      adjustments to reconcile net income from continuing operations to net cash from operating activities:
    		                                                 
      net cash from financing activities - continuing operations
    		            1,187,000 -67,000 1,208,000  -250,985,000 -503,458,000 7,261,000                               
      proceeds from public offering of common stock, net of reimbursements
    		                                                 
      operating lease liabilities arising from obtaining operating lease assets
    		                       0 -534,000                         
      non-cash interest expense associated with the sale of future revenue
    		                   6,014,000 9,767,000                             
      non-cash royalty revenue
    		                   -2,953,000 -2,691,000                             
      collaboration receivable – related party
    		                   211,000 203,000 40,000 -1,038,000 299,000 686,000 -205,000 143,000 933,000 15,931,000 -15,814,000 -1,064,000 1,041,000 1,353,000 6,423,000 -6,379,000 3,296,000 -329,000 -1,039,000 1,411,000 852,000 1,397,000 -3,458,000 -524,000 12,267,000      
      collaboration receivable – other
    		                   44,000 -165,000 206,000 -105,000 -1,059,000 1,353,000 -582,000 -970,000 -230,000 0                     
      royalty receivable – related party
    		                   0 1,650,000 1,650,000 -400,000 -300,000 100,000 -500,000 34,000 -371,000 -290,000 -156,000 -195,000 -507,000                  
      deferred revenue – related party
    		                   0 0 -4,748,000 -56,765,000 -5,157,000 -3,400,000 -7,058,000 -15,391,000 -15,916,000 -5,105,000 -7,503,000 -3,141,000 -6,429,000 -8,957,000 -9,260,000 -1,924,000 -20,146,000 -4,653,000 196,537,000 -5,892,000 -4,525,000 -3,108,000 24,979,000 -31,393,000 -6,789,000 -15,141,000     
      deferred rent
    		                           -138,000 72,000 -112,000 96,000 -210,000 -866,000 -852,000 -801,000 -820,000 1,353,000 1,373,000 -560,000 256,000 1,860,000 5,471,000 8,218,000 3,611,000 135,000 -31,000 -24,000   
      reimbursement (payment) of public offering costs
    		                                                 
      proceeds from the sale of future revenue, net of issuance costs
    		                   0 0                             
      proceeds from stock option exercises in other current assets
    		                         -1,037,000 1,149,000 -32,000   73,000    6,000   6,000 17,000 -14,000 197,000 -57,000 60,000 -164,000      
      net accretion of premium and discounts on investments
    		                    1,048,000 347,000 126,000  -753,000                         
      depreciation
    		                     2,432,000 2,474,000  2,082,000 2,037,000 2,005,000 1,911,000 1,797,000 1,739,000 1,725,000 1,654,000 1,614,000 1,573,000 1,591,000 1,722,000 1,436,000 1,304,000 1,246,000 1,145,000 1,047,000 780,000 370,000 362,000 346,000 327,000 332,000 340,000 377,000 
      payment of public offering costs, net of reimbursements
    		                            0 -203,000 -188,000                   
      proceeds from public offering of common stock, net of commissions
    		                            0 0 516,206,000 0 0   0              
      net amortization of premium and discounts on investments
    		                          -1,131,000  -1,249,000 -885,000 -406,000  -69,000 -69,000 163,000  204,000 204,000 126,000    172,000       
      public offering costs in other current assets, net of amounts in accounts payable and accrued expenses
    		                                   106,000              
      (payment) reimbursement of public offering costs
    		                                                 
      public offering costs in other receivables, net of amounts in accounts payable and accrued expenses
    		                                193,000                 
      tenant improvement and other receivables
    		                               372,000 -80,000 2,662,000 -24,000 4,000 -1,089,000 -1,443,000 2,803,000           
      public offering costs in other current assets
    		                                  329,000               
      public offering costs in accounts payable and accrued expenses
    		                              158,000                   
      refundable income taxes and income taxes payable
    		                                       0 0 0 3,841,000 0 0 655,000 -5,958,000   
      net proceeds from stock option exercises and employee stock purchase plan, and vesting of restricted stock units
    		                                                 
      vesting of restricted stock
    		                                       12,000 -2,000 -6,000 2,000 16,000 -1,000 -9,000 3,000   
      proceeds from stock option exercises in other receivables
    		                                92,000                 
      adjustments to reconcile net income cash from operating activities:
    		                                                 
      reimbursement of public offering costs, net of payments
    		                                                 
      loss on disposal of fixed assets
    		                                  40,000               
      accrued expenses and other liabilities
    		                                  -6,889,000  8,161,000 2,069,000 -2,902,000 -836,000 5,027,000 -4,132,000 1,574,000 1,817,000 4,544,000 1,064,000 -2,194,000 2,398,000 635,000 
      payment of public offering costs
    		                                  -100,000 -106,000       -207,000       
      net income on disposal of fixed assets
    		                                                 
      net amortization of premiums and discounts on marketable securities
    		                                                 
      release of restricted cash
    		                                           0      
      net proceeds from stock option exercises and employee stock purchase plan and vesting of restricted stock units
    		                                                 
      net increase in cash and cash equivalents
    		                                   -124,748,000 51,454,000 195,013,000 -32,729,000 -8,284,000 7,515,000 37,277,000 21,225,000  -38,198,000   -34,451,000  
      supplemental cash flow information
    		                                                 
      cash paid for income taxes
    		                                           22,000 0 0 5,958,000   
      additions to property, plant and equipment included in accounts payable and accrued expenses
    		                                                 
      additions to property, plant and equipment in accounts payable and accrued expenses
    		                                    -863,000 753,000 607,000    6,602,000       
      prepaid expenses and other assets
    		                                     -272,000 -857,000 -1,451,000 -2,442,000 833,000 -708,000 -122,000 -1,965,000 139,000 -930,000 122,000 1,006,000 
      deferred taxes
    		                                                 
      net amortization of premiums and discounts on investments
    		                                                 
      proceeds from private placement
    		                                                 
      net proceeds from stock option exercises and issuance of common stock
    		                                            380,000 454,000 582,000   
      conversion of convertible preferred stock upon initial public offering
    		                                                 
      net amortization of premium on investments
    		                                        112,000         
      net proceeds from public offering of common stock, (payment of) commissions and offering costs
    		                                        0         
      net proceeds from stock option exercises and issuance of common and restricted common stock
    		                                                 
      net decrease in cash and cash equivalents
    		                                              -38,723,000   
      proceeds from public offering of common stock, net of commissions and offering costs
    		                                            -13,000     
      additions to property, plant and equipment included in accounts payable
    		                                            185,000 -1,000 13,000   
      conversion of convertible preferred stock into common stock
    		                                                 
      public offering costs included in accounts payable
    		                                                 
      net amortization (accretion) of premium (discount) on investments
    		                                             137,000 168,000   
      unbilled collaboration receivable – related party
    		                                                 
      unbilled collaboration receivable—related party
    		                                              -2,143,000   
      deferred revenue—related party
    		                                              -6,268,000   
      accrual of public offering costs
    		                                              65,000   
      unbilled collaboration receivable
    		                                                 
      proceeds from initial public offering, net of commissions
    		                                                 
      payment of initial public offering costs
    		                                                 
      net proceeds from issuance of series c convertible preferred stock
    		                                                 
      amortization (accretion) of premium (discount) on investments
    		                                                 
      proceeds from initial public offering and private placement of common stock
    		                                                 
      net proceeds from stock option exercises
    		                                                 
      non-cash financing activities
    		                                                 
      initial public offering costs incurred but unpaid at period end
    		                                                 
      amortization of (discount) premium on investments
    		                                                 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.